Inotuzumab Ozogamicin, a Nonchemotherapy Option for Relapsed Acute Lymphoblastic Leukemia

  H&O  What percentage of patients with ALL will develop relapsed disease, and what is their prognosis? HK  Among adult and elderly patients with acute lymphoblastic […]

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia 

  Abstract: Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in […]